InvestSMART

Opyl Limited (ASX:OPL)

ALERT: Price-sensitive ASX Announcement for OPL
Current share price for OPL : $0.022 0 (0%)+
Announcement
Release
30 Jul 2025 12:34PM
Price at Release
$0.022
Full Release
download
Summary
Opyl Limited released its Quarterly Activities and Cashflow Report for the period ending 31 December 2023. The report details progress across the company's core clinical trial recruitment platforms, Opin (AI-driven clinical trial recruitment) and TrialKey (clinical trial feasibility and protocol design). During the quarter, Opyl focused on improving trial recruitment and retention, enhancing platform features, and building commercial partnerships. The company reported increased revenues and advances in pipeline activity, with ongoing contract wins and customer engagement. Operational improvements were highlighted, including extending runways through cost control, and strategic investment in technology. The Appendix 4C cashflow statement shows prudent cash management and outlines expenditure and receipts for the quarter.
Key Points
  • Quarterly report covers period ending 31 December 2023.
  • Opyl Limited operates Opin and TrialKey, AI-driven clinical trial platforms.
  • Continued growth in trial recruitment and retention, with product enhancements.
  • Revenue increased due to new and recurring customers.
  • Implemented cost controls to extend operational runway.
  • Strategic investment in AI and technology platforms.
  • Reported ongoing and new contracts in the clinical trial sector.
  • Appendix 4C cashflow shows receipts, expenditures and cash position.
  • Board and management focus on commercial execution and financial prudence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.